Boston Scientific (NYSE:BSX) today announced the commercial launch of its Polaris imaging software, an upgrade to the company’s iLab system that aims to make intravascular imaging simpler and more powerful.
The Polaris program comes with features designed to make it easier to use and provide more helpful information to guide clinical decisions. The technology supports Boston Scientific’s existing suite of intravascular ultrasound catheters and provides a platform for the company to launch new imaging products.
Such new products include "a fractional flow reserve wire, a new family of IVUS catheters, enhanced software features and better system control tools," according to a press release.
The Polaris software is already approved in Europe and cleared for the U.S. and has been evaluated in hospitals in both markets, Boston Scientific said.
"The Polaris System is an advance for intravascular imaging," MedStar Washington Hospital Center’s Dr. Lowell Satler said on behalf of the company. "The improved ease-of-use and image processing simplifies the procedure and enables our team to quickly obtain the information needed to treat patients."
The win is more good news for Boston Scientific, which earlier this week announced FDA approval for its Rebel bare-metal stent. The company last week also announced a CE Mark win for the 25 mm size of its Lotus aortic valve and for its Ranger drug-eluting balloon.
BSX shares gained a few points today, trading at a 3.2% increase of $12.95 as of about 12:45 p.m. EST. The stock is up 7.8% since the start of the year.